This study uses one trialdrug: Temsirolimus (sometimes called Torisel ® ). Temsirolimus is an
mTOR inhibitor. It is an agent that is specifically aimed at disrupting cell division (needed
for cancer cell growth). Temsirolimus has been shown to inhibit the growth of cancer cells.
For patients with metastatic kidney cancer Temsirolimus is now a registered , conventional
therapy. It has been recorded for patients as they get renal cell cancer metastases and which
looks as if the tumor is aggressive.
This is a phase II trial. This means that the investigators look at how effectively
temsirolimus is, after treatment with other drugs against kidney cancer. Effective means that
the investigators see how well the treatment is, the investigators look at how long the
disease is not growing and if it does, that is smaller. The possible side effects will be
carefully watched.